What causes vaginal dryness during peri- and post-menopause?
Vaginal dryness in peri- and post-menopause mainly stems from lower oestrogen (and androgen) levels. The vaginal lining becomes thinner, less elastic and less well-lubricated; pH rises and protective lactobacilli fall, so friction causes stinging, burning and micro-tears. Stress, some medicines, smoking, alcohol, and high-friction activities can aggravate symptoms. Moisturisers, the right lubricant and, if needed, local oestrogen or DHEA often help over weeks. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
What causes vaginal dryness during peri- and post-menopause? During the menopausal transition, ovarian production of oestrogen (and, to a lesser degree, androgens) declines. Oestrogen receptors in the vulva, vagina, urethra and bladder help maintain tissue thickness, elasticity, blood flow, and natural lubrication. With lower hormone levels, the vaginal epithelium thins and loses its corrugations (rugae), glycogen stores fall, and the vaginal pH rises as protective lactobacilli diminish. This combination—often described as vaginal atrophy within the modern umbrella of genitourinary syndrome of menopause (GSM)—leads to dryness, friction, stinging with urine on delicate skin, and superficial fissures or micro-tears. Dyspareunia (pain with sex) may follow when lubrication is insufficient or the entrance feels tight.
Why pH and the microbiome matter. An acidic vaginal environment supported by lactobacilli helps protect against irritation and some infections. As pH rises in menopause, the mucosa becomes more vulnerable. Even everyday activities—long walks, cycling, inserting tampons or menstrual cups—can feel “scratchy” when the lining is dry. The vestibule (entrance) is especially sensitive, so pain can be concentrated there even if the deeper vagina feels comfortable.
Other contributors beyond hormones. Several non-hormonal factors can worsen dryness or make it more noticeable: 1) Products/irritants (fragranced washes, wipes, bubble baths, perfumed liners) can strip oils and inflame sensitive skin. 2) Medications with anticholinergic or drying effects (some antidepressants, antihistamines, antimuscarinics), acne therapies like isotretinoin, and some cancer treatments reduce secretions or alter mucosa. 3) Lifestyle: smoking, heavy alcohol, low hydration, and high-friction clothing increase irritation. 4) Life stages and health conditions: postpartum/breastfeeding, surgical menopause, autoimmune skin conditions (e.g., lichen sclerosus), pelvic floor overactivity, or persistent stress (which can reduce arousal and lubrication) add layers to the picture.
What this feels like day to day. Early signs include reduced baseline moisture, slower or shorter-lived arousal lubrication, and a sandpaper-like sensation with friction. Some notice stinging after sex, spotting from micro-tears, or discomfort inserting a speculum. Urinary urgency or frequency can appear alongside vaginal symptoms because the urethra and bladder trigone are oestrogen-responsive. Not every symptom is dryness, though; infections (thrush, bacterial vaginosis), contact dermatitis, vestibulodynia or dermatological conditions can mimic or compound GSM and need specific care.
Practical first steps. Foundations matter: use lukewarm water to rinse, a bland emollient as a soap substitute externally, and breathable underwear. Schedule a vaginal moisturiser several times per week to rehydrate tissue (some contain hyaluronic acid), and keep a personal lubricant for intimacy/examinations—water-based (versatile, condom-friendly), silicone-based (longer-lasting glide for significant dyspareunia), or oil-based (rich feel but can degrade latex condoms and some toys). Allow unhurried arousal and try positions that reduce stretch at the entrance. If you’re mapping out how care is delivered, see our overview of what treatments involve and how steps are sequenced in the clinic.
When to escalate. If symptoms persist, local vaginal oestrogen (cream, tablet/pessary, or estradiol-releasing ring) can restore the mucosal environment and improve comfort over weeks. Vaginal DHEA is another local option. Systemic HRT can help vasomotor symptoms but often needs to be paired with local therapy for GSM. Pelvic health physiotherapy addresses muscle guarding from pain; psychosexual therapy supports confidence and reduces fear-avoidance patterns. Advanced options (energy-based devices such as laser/radiofrequency, or regenerative injectables like platelet-rich plasma or polynucleotides) are not first-line and should be considered cautiously, balancing evidence, safety and cost against goals.
Where to read more. See the NHS overview of vaginal dryness for plain-language symptoms and self-care; the NICE Menopause Guideline (NG23) for step-wise management; prescriber details in the British National Formulary (BNF); randomised evidence syntheses in the Cochrane Library; and peer-reviewed overviews of GSM and related terms on PubMed.
Clinical Context
Who is more likely to experience bothersome dryness? People in late perimenopause or after periods stop; those with earlier menopause, bilateral oophorectomy (surgical menopause), or who cannot/choose not to use systemic HRT; and individuals with sensitive skin or dermatological conditions. Breastfeeding can temporarily mirror menopausal dryness because oestrogen is low. High-friction activities (distance cycling, running) and fragranced products can unmask symptoms sooner. Urinary urgency/frequency may accompany vaginal symptoms because urethral tissue is also oestrogen-responsive.
Who should seek assessment first? Anyone with severe or recurrent symptoms despite sensible self-care; new malodorous discharge, cottage-cheese-like discharge, or fishy odour; fever, pelvic pain; visible ulcers/white patches; post-menopausal bleeding; or visible blood in urine. A clinician can distinguish GSM from thrush/BV, lichen sclerosus or contact dermatitis, and rule out infection. If there is a history of hormone-sensitive cancer, discuss local oestrogen or DHEA with oncology and menopause teams to balance benefits and risks. Plan a review after 6–12 weeks to adjust to the lowest effective maintenance once comfortable.
Evidence-Based Approaches
Guidelines recommend starting with non-hormonal support (vaginal moisturisers and suitable lubricants) and escalating to local oestrogen when symptoms affect quality of life. The NICE Menopause Guideline (NG23) sets out this step-wise approach and notes that local oestrogen can be used with or without systemic HRT. Product choice—estradiol/estriol creams, pessaries/tablets, or an estradiol ring—depends on preference, dexterity and symptom pattern; many continue long-term maintenance at the lowest effective dose.
Cochrane reviews summarise randomised trials showing that low-dose vaginal oestrogens improve dryness, soreness, dyspareunia and vaginal pH versus placebo, with broadly similar efficacy across formulations and low systemic absorption at licensed doses. See the Cochrane Library for methodology and pooled estimates. NHS resources on vaginal dryness outline practical self-care and red flags, while the BNF provides UK product information, cautions and interactions relevant to prescribers and informed patients.
Peer-reviewed summaries indexed on PubMed explain GSM’s mechanisms (thinner epithelium, raised pH, loss of lactobacilli), the role of vaginal DHEA, and when to consider pelvic floor and psychosexual approaches. Evidence for energy-based devices (laser/radiofrequency) and regenerative injectables (PRP/polynucleotides) is evolving and these are not first-line; decisions should weigh uncertainties, regulatory status, costs and personal goals. Hyaluronic-acid moisturisers can be helpful for those avoiding hormones, though effects are usually smaller and depend on regular, ongoing use.